Recent progress on polySarcosine as an alternative to PEGylation: Synthesis and biomedical applications

  • Int J Pharm. 2024 Mar 25:653:123871. doi: 10.1016/j.ijpharm.2024.123871.
Mohamed Fawzi Kabil  1 ,  Hassan Mohamed El-Said Azzazy  1 ,  Maha Nasr  2
Affiliations
  • 1. Department of Chemistry, School of Sciences and Engineering, The American University in Cairo, AUC Avenue, New Cairo 11835, Egypt.
  • 2. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address: [email protected].
PMID: 38301810 DOI: 10.1016/j.ijpharm.2024.123871
Abstract

Biotherapeutic PEGylation to prolong action of medications has gained popularity over the last decades. Various hydrophilic natural Polymers have been developed to tackle the drawbacks of PEGylation, such as its accelerated blood clearance and non-biodegradability. Polypeptoides, such as polysarcosine (pSar), have been explored as hydrophilic substitutes for PEG. pSar has PEG-like physicochemical characteristics such as water solubility and no reported cytotoxicity and immunogenicity. This review discusses pSar derivatives, synthesis, characterization approaches, biomedical applications, in addition to the challenges and future perspectives of pSar based biomaterials as an alternative to PEG.

Keywords
Biomedical applications; Polyethylene glycol; Polypeptoids; Polysarcosine.
Products